Despite growing fears of a global economic recession and deteriorating investor sentiment in the stock market, the Korean pharmaceutical industry began releasing year-end dividends and issuing free additional shares.Celltrion, Celltrion Healthcare, and Celltrion Pharma, recently decided to pay divid
Korea United Pharm is experiencing difficulties turning its plan to enter the Chinese market with incrementally modified drugs (IMDs) into a reality.In a public disclosure Monday, Korea United Pharm announced that the company has terminated its contract with Jiangxi JiminKexin Group (JJK) to supply
MSD Korea said on Monday that it has selected Boryung Biopharma as the new distributor and supplier of its pneumococcal vaccine, Prodiax 23.Accordingly, from January 1, 2023, both MSD Korea's Prodiax 23 and the national immunization program (NIP) products will be distributed and supplied by Boryung
Hyundai Pharm said Monday that it would reapply for the permit of Mifegymiso (mifepristone/misoprostol), an oral abortion drug, to the Ministry of Food and Drug Safety.“We have submitted most supplementary data according to the review results of the Ministry of Food and Drug Safety, but failed to pr
JW Pharmaceutical said Monday that epaminurad (pipeline name: URC102), a gout treatment, proved its safety in nephropathy patients in a phase 1 trial.Epaminurad, an oral medicine, is a uricosuric that restrains URAT1(uric acid transporter-1), according to the company. It is believed to be effective
Antibody-Drug Conjugates (ADCs), which drew attention by supplementing existing drugs’ shortcomings, have emerged as a major new anticancer drug platform, recording a market growth rate of 22 percent.Korea Drug Development Fund (KDDF) released a report on the global trend of new drug development con
AstraZeneca Korea will challenge to treat gastric adenocarcinoma with the combination therapy of bispecific antibody candidate substances.The Ministry of Food and Drug Safety approved on Thursday phase 2 clinical trial on the efficacy and safety of the combo therapy of MED15752 and AZD2936 on patien
LG Chem said Thursday that it had signed an agreement to transfer the exclusive right to develop and commercialize its new gout drug, Tigulixostat, in China, to Innovent Biologics, a Chinese pharmaceutical company.LG Chem has secured an upfront payment of $10 million, and can receive up to $85.5 mil
The Health Insurance Review and Assessment Service (HIRA) said it would operate a system to manage “super-expensive” drugs, such as Kymriah and Zolgensma, including their course of medication.The state-run agency said Wednesday that it would run the system to “manage expensive drugs” to enhance the
GC Wellbeing has signed a technology transfer and joint development agreement for GCWB204, its cancer cachexia treatment candidate, with MThera Pharma.In a European phase 2a clinical trial last year, GC Wellbeing confirmed the potential of GCWB204 as a treatment for cancer cachexia in multiple evalu
Lilly Korea's CDK4/6 inhibitor Verzenio (ingredient: abemaciclib) will be an alternative treatment for the complete recovery of early breast cancer patients with a high risk of recurrence, the company said Wednesday.In November, Lilly Korea obtained expanded indication approval from the Ministry of
SK Biopharmaceuticals presented the company’s roadmap and vision for its digital healthcare business ahead of CES 2023 at a media briefing in Seoul on Wednesday.For instance, SK Biopharma’s “Project Zero” aims to become a total healthcare solution provider by developing wearable devices converged wi
Helixmith said Wednesday that it has developed a new freeze-drying formulation for its gene therapy, Engensis (VM202), further improving advantages in its manufacturing process and obtaining a patent in the U.S.The new formulation forms a superior cake quality and increases the stability of Engensis
As China abandons its “zero-Covid” policy, the Korean pharmaceutical companies are guessing whether it would work as a crisis or an opportunity.The Chinese government issued quarantine guidelines that allowed people infected with Covid-19 to self-isolate and significantly eased the polymerase chain
Celltrion said Tuesday it has proved once again the safety and effectiveness of Truxima(ingredient: rituximab), a hematologic malignancy treatment, through the internal post-marketing surveillance(PMS) at the American Society of Hematology (ASH) 2022.The clinical trial is the data on 677 safety eval
A heated debate is going on whether to view the three CDK4/6 inhibitors – Ibrance, Kisqali, and Verzenio -- in treating breast cancer as the same drug group or as individual drug groups.These CKD (cyclin-dependent kinase)4/6 inhibitors are said to have changed the treatment paradigm of HR+ (hormone
SillaJen will increase corporate value by increasing the company’s capabilities to research and develop new drugs, its top manager said.SillaJen CEO Kim Jae-kyung remarked at a news conference Tuesday to present the company’s current R&D status and plans after resuming its stock trading in the tech-
LG Chem said Tuesday that it confirmed the safety and efficacy of Zemidapa as a dual add-on therapy for type 2 diabetes patients who do not respond well to metformin standard diabetes treatments in phase 3 clinical trial.Zemidapa combines Zemiglo (ingredient: gemigliptin), a type 2 diabetes treatmen
The court has postponed the initial ruling over the civil lawsuit between Medytox and Daewoong Pharmaceutical over the origin of the latter's botulinum toxin strains to next year.The suit is regarding Medytox filing a civil lawsuit against Daewoong, claiming that the latter stole the BTX strain thro
GC Biopharma said on Monday that its I.V.-Globulin SN inj. 10% (ingredient: human immunoglobulin-G) for treating autoimmune encephalitis patients demonstrated safety and efficacy in prospective clinical trials.Autoimmune encephalitis is a disease that causes neurological deficits through autoimmune